Clinical use of cytomedin in patients with prostate diseases
Authors:   Federal Medical and Biological Center named after A.I. Burnazyana FMBA RF, Moscow, Russia, Ergakov D.V. , Martov A.G. ,   Federal Medical and Biological Center named after A.I. Burnazyana FMBA RF, Moscow, Russia
Published: September 2021

Introduction. The use of extracts of the prostate of animals is one of the main directions in the treatment of patients with diseases of the prostate. Most studies describe the experience of using these drugs in a small number of patients for a limited time period. The aim of this work was to summarize the long-term experience of using drugs of the cytomedin group in the treatment of a large number of patients with chronic prostatitis (CP) and benign prostatic hyperplasia (BPH). Materials and methods. Cytomedins were used in 487 patients with CP / BPH from January 2015 to December 2018. Indications: rehabilitation of patients after pancreatic biopsy (63 patients, 13%), cystoscopy and other endoscopic surgical interventions (189 patients, 39%), as well as conservative therapy of chronic inflammation associated with BPH (235 patients, 48%). If an infectious-inflammatory process was suspected, the following scheme was used: Vitaprost Plus 1 candle 1 time per day for 20 days, in the presence of irritative complaints, Vitaprost Forte was used 1 candle 1 time per day for 20 days, in other cases Vitaprost was prescribed 1 candle 1 time per day for 20 days ... The second component of the complex treatment was the use of the Vitaprost tablet form for 20 days, 1 ton 2 times a day. Before and after the appointment of therapy, the quality of life was monitored according to the data of the visual analogue scale (VAS), ultrasound examination of the pancreas (ultrasound) and laboratory parameters. The results of therapy were assessed as successful with an improvement in the quality of life, a decrease in the level of leukocytes, and a decrease in the volume of the pancreas by more than 10% from the initial level. Results. The total efficacy of cytomedin therapy was 39%. The greatest effectiveness of therapy was with the initial VAS less than 60 points out of 100; with more severe pain syndrome, the effectiveness was statistically significantly reduced to 32%. The initial detection of an inflammatory component with an increase in the level of leukocytes in laboratory tests statistically significantly increased the effectiveness of therapy 48 versus 24%. Cytomedin therapy was equally effective regardless of the prostate volume (36% versus 42% versus 38%, p> 0.05). A survey was conducted in 102 patients after Vitaprost-Forte / Vitaprost therapy, the results of which revealed a decrease in the I-PSS score from 18 ± 6.4 points to 12 ± 4 points (p> 0.05), in the group with combination therapy with alpha adrenergic blockers – 8 ± 3.2 points, p <0.05. A control examination of 51 patients with the development of erectile dysfunction against the background of chronic intake of 5-ARI showed that the cancellation of 5-ARI inhibitors followed by the appointment of Vitaprost in the form of suppositories and tablets led to an increase in the IIEF-5 indicator by 5 points, the average indicator during the control examination was 23 ± 4.2 points (p> 0.05) versus 18 ± 3.4 points before treatment. Conclusions. the following prognostic criteria for the effectiveness of cytomedin therapy were determined: the level of the visual analogue scale is less than 60 out of 100 and the presence of a confirmed inflammatory component according to laboratory tests.